文献速递支持与姑息治疗骨软组织肉瘤与黑色素瘤

MAK683(EED抑制剂)在晚期恶性肿瘤患者中的首次人体1/2期剂量递增研究

A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.
PubMed 文献 · Eur J Cancer · 2024-11-16

MAK683是一种首创的高选择性PRC2复合物EED亚基变构抑制剂,在肿瘤异种移植模型中显示持续抗肿瘤活性。本首次人体1/2期研究评估单药MAK683在晚期恶性肿瘤中的安全性、药代动力学和临床活性,共139例患者接受治疗,中位暴露57天,15例发生22例次剂量限制性毒性,中位无进展生存期1.9个月,总缓解率5.8%,在晚期弥漫大B细胞淋巴瘤和上皮样肉瘤中观察到临床活性。

要点

  • MAK683单药在晚期恶性肿瘤中总体耐受性良好,常见3/4级药物相关不良事件包括中性粒细胞减少、血小板减少和贫血。
  • 15例患者发生22例次剂量限制性毒性,包括血小板减少(4.9%)和发热性中性粒细胞减少(3.3%)。
  • 中位无进展生存期1.9个月(90%CI 1.8-2.3),总缓解率5.8%(90%CI 2.52-11.03%)。

核心结论

  • MAK683治疗总体耐受性良好,在晚期弥漫大B细胞淋巴瘤和上皮样肉瘤患者中观察到临床活性。

研究设计与样本

  • 首次人体1/2期剂量递增研究,评估单药MAK683在晚期恶性肿瘤患者中的安全性、药代动力学和临床活性。
  • MAK683空腹状态下每日一次或每日两次连续给药,28天为一个治疗周期。
  • 共139例患者接受MAK683治疗,包括卵巢透明细胞癌9例(6.5%)、去势抵抗性前列腺癌22例(15.8%)、弥漫大B细胞淋巴瘤31例(22.3%)、上皮样肉瘤17例(12.2%)、胃癌37例(26.6%)、鼻咽癌17例(12.2%)、SWI/SNF突变肉瘤6例(4.3%)。
  • 安全性评估包括剂量限制性毒性的性质以及不良事件和严重不良事件的发生率和严重程度。
  • 药代动力学通过第1-6周期连续血样评估,药效动力学通过H3K27me3较基线的变化评估。

主要发现

  • 中位暴露时间为57天(范围:4-1006天)。
  • 15例患者发生22例次剂量限制性毒性,包括血小板减少(4.9%)和发热性中性粒细胞减少(3.3%)。
  • 98例患者(70.5%)报告MAK683相关不良事件;43例患者发生3/4级药物相关不良事件,包括中性粒细胞减少、血小板减少和贫血。
  • MAK683吸收迅速,峰值血浆浓度时间为0.975至4.08小时。
  • 中位无进展生存期为1.9个月(90%置信区间:1.8-2.3),总缓解率为5.8%(90%置信区间:2.52-11.03%)。

关键数值与推荐

  • 剂量限制性毒性:15例患者发生22例次,包括血小板减少(4.9%)和发热性中性粒细胞减少(3.3%)。
  • MAK683相关不良事件发生率70.5%(98例),3/4级药物相关不良事件43例。
  • 中位无进展生存期1.9个月(90%CI 1.8-2.3),总缓解率5.8%(90%CI 2.52-11.03%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: MAK683, a first-in-class and highly selective allosteric inhibitor of the embryonic ectoderm development subunit of polycomb repressive complex 2, has shown sustained antitumor activity in tumor xenograft models. This first-in-human phase 1/2 study evaluated the safety, pharmacokinetics (PK), and clinical activity of single-agent MAK683 in advanced malignancies. METHODS: MAK683 was administered fasted once daily or twice daily continuously in 28-day treatment cycles. Safety assessments included the nature of dose-limiting toxicities (DLTs) and the incidence and severity of adverse events (AEs) and serious AEs. The PK profile of MAK683 was assessed in sequential blood samples of cycles 1-6, and pharmacodynamic profiles were measured by H3K27me3 changes from baseline. RESULTS: Overall, 139 patients (clear cell carcinoma of the ovary [CCCO], 9 [6.5%]; castration-resistant prostate cancer [CRPC], 22 [15.8 %]; diffuse large B-cell lymphoma [DLBCL], 31 [22.3%]; epithelioid sarcoma [ES], 17 [12.2 %]; gastric cancer [GC], 37 [26.6 %]; nasopharyngeal carcinoma [NPC], 17 [12.2 %]; SWI/SNF-mutated sarcoma, 6 [4.3 %]) received MAK683. Median duration of exposure was 57 days (range: 4-1006). Fifteen patients experienced 22 DLTs including thrombocytopenia (4.9 %) and febrile neutropenia (3.3 %). MAK683-related AEs were reported in 98 patients (70.5 %); 43 patients had grade 3/4 drug-related AEs, including neutropenia, thrombocytopenia, and anemia. MAK683 was quickly absorbed, with peak plasma concentrations ranging from 0.975 to 4.08 h. Median progression-free survival was 1.9 months (90 % confidence interval [CI]: 1.8-2.3), and overall response rate was 5.8 % (90 % CI: 2.52-11.03 %). Clinical activity was observed in patients with advanced DLBCL and ES. CONCLUSION: Overall, MAK683 treatment was well tolerated, and clinical activity was observed in patients with advanced DLBCL and ES. CLINICAL TRIAL INFORMATION: NCT02900651.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ribrag V, Iglesias L, De Braud F, et al. A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies. Eur J Cancer. 2024. PMID: 39793445. doi:10.1016/j.ejca.2024.115122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。